Artios Pharma

Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer approach and the deep experience of its team of DDR drug developers. The companys clinical-stage candidates, ATR inhibitor alnodesertib and DNA Polymerase theta (Pol) inhibitor ART6043, as well as its pre-clinical programs, i... ncluding DDRi-ADCs, are designed with differentiated pharmaceutical properties and novel biological approaches to precisely eliminate a cancer cells remaining survival mechanisms. Artios mission is to develop new classes of medicines that exploit DDR pathways with the aim of improving outcomes for patients with hard-to-treat cancers.Read More